Anti-CD3 Antibodies T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for anti-CD3 antibodies that can effectively bind and activate CD3 expressing T cells for cancer therapeutic purposes, as existing solutions are inadequate in this regard.
Innovation Solution
Development of anti-CD3 antibodies comprising specific light and heavy chain variable domains with defined complementarity-determining regions (CDRs) that enable binding to CD3 antigens, including recombinant proteins and pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CD3 antibodies are used, then T cell binding is achieved, but adequate activation of CD3 expressing T cells for cancer therapy is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's binding characteristics and activation properties. Specifically, the anti-CD3 antibody is engineered to bind CD3 with optimized affinity and induce specific activation signals that enhance T cell response against cancer cells, transforming the antibody's functional parameters to achieve both reliable binding and therapeutic activation
Solution Approach 2:
The anti-CD3 antibody serves as an intermediary molecule that bridges the gap between T cells and cancer cells. By binding to CD3 on T cells and engaging tumor-associated antigens, the antibody mediates T cell activation and directs immune response toward cancer cells, enabling therapeutic efficacy that neither component could achieve alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively activate CD3 expressing T cells, providing a therapeutic approach for cancer treatment by enhancing immune response against cancer cells.
Implementation Method 1
anti-CD3 antibodies that bind and activate CD3 expressing T cells
Data Source
AI summary
Provided herein are, inter alia, antibodies capable of binding human and non-human primate (e.g., cynomolgus) CD3. The anti-CD3 antibodies provided herein including embodiments thereof may be used for therapeutic purposes, for example, as humanized anti-CD3 antibodies, or they may form part of bispecific antibodies. Further provided herein are, inter alia, non-CD3 binding antibodies that are derived from the anti-CD3 antibodies provided herein including embodiments thereof, and which due to the presence of amino acid substitutions have lost their ability to bind to CD3.